+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease



Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease



Mikrobiyoloji Bulteni 45(1): 181-195



Drug resistance in tuberculosis is a growing global problem. The emergence of multi-drug resistant tuberculosis cases, particularly in the 1990s, has become an important health problem and threatens tuberculosis control worldwide. Resistance to isoniazid and rifampicin, two of the most potent anti-tuberculosis drugs currently available, in multi-drug resistant tuberculosis cases is clinically quite important. The treatment of multi-drug resistant tuberculosis requires prolonged use of costly second-line drugs with significant toxic potentials under supervision and long-term hospitalization of patients. The appropriate management of tuberculosis, clinical/radiological and bacteriological follow-up, and surgery when needed are essential factors in the successful treatment of multi-drug resistant tuberculosis patients. An extensively drug resistant tuberculosis outbreak seen in KwaZulu-Natal region of the Republic of South Africa in 2005 led to certain doubts worldwide; this outbreak, introduced the importance and emergence of the counter measures against multi-drug resistant tuberculosis cases. Extensively drug resistant tuberculosis is defined as resistance to at least isoniazid and rifampicin from the first-line anti-tuberculosis drugs (the definition of multi-drug resistant tuberculosis) in addition to resistance to any fluoroquinolone, and to at least one of the three injectable second-line anti-tuberculosis drugs (kanamycin, capreomycin and amikacin) used in tuberculosis treatment. Mistreatment of multi-drug resistant tuberculosis cases by physicians, the use of anti-tuberculosis drugs with low quality, poor experience in management, lack of laboratories to perform second-line anti-tuberculosis drug susceptibility testing and problems in adherence of patients to treatment are factors associated to the development of extensively drug resistant tuberculosis. With the emergence of extensively drug resistant tuberculosis, World Health Organization gives importance to the mycobacteriology laboratory improvement, better multi-drug resistant tuberculosis case management, adequate drug supply, prevention of tuberculosis transmission and development of new drugs and diagnostics. Recently, a new form of tuberculosis, resistant to all first-and second-line anti-tuberculosis drugs seen in just a few number of cases, has been defined as extremely drug resistant tuberculosis and this is the end point in resistance problem in tuberculosis. In the view of this situation the stages of tuberculosis in terms of developing resistance are as follows: drugsensitive tuberculosis, mono-drug resistant tuberculosis, poly-drug resistant tuberculosis, multi-drug resistant tuberculosis, extensively drug resistant tuberculosis, and extensively drug resistant tuberculosis. In this review, the recent information about drug resistant tuberculosis forms, particularly extremely drug resistant tuberculosis that has been popular since 2005, has been discussed.

(PDF emailed within 1 workday: $29.90)

Accession: 053164165

Download citation: RISBibTeXText

PMID: 21341173


Related references

Extensively and pre-extensively drug resistant tuberculosis in clinical isolates of multi-drug resistant tuberculosis using classical second line drugs (levofloxacin and amikacin). Journal of the College of Physicians and Surgeons--Pakistan 25(5): 337-341, 2016

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 136(2): 420-425, 2009

The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology 18(5): 289-291, 2008

The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 15: 434, 2015

Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades. Microbial Genomics 4(2), 2018

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. International Journal of Antimicrobial Agents 49(6): 688-694, 2017

Pathogenesis of multi drug-resistant and extensively drug-resistant tuberculosis as a determinant of future treatment success. International Journal of Mycobacteriology 5 Suppl 1: S64-S65, 2017

A cross-sectional study about knowledge and attitudes toward multidrug-resistant and extensively drug-resistant tuberculosis in a high-burden drug-resistant country. International Journal of Mycobacteriology 5(2): 128-134, 2018

Epidemiology of multidrug-resistant, extensively drug resistant, and totally drug resistant tuberculosis in Middle East countries. International Journal of Mycobacteriology 5(3): 249-256, 2018

Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clinical Infectious Diseases 54(6): E51-E54, 2012

Predominance of Beijing lineage among pre-extensively drug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis: A tertiary care center experience. International Journal of Mycobacteriology 5 Suppl 1: S197-S198, 2017

Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate. Antimicrobial Agents and ChemoTherapy 57(6): 2522-2525, 2013

Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP. Iranian Journal of Microbiology 4(4): 165-170, 2012

Einstein Contained Aerosol Pulmonizer (ECAP): Improved Biosafety for Multi-Drug Resistant (MDR) and Extensively Drug Resistant (XDR) Mycobacterium tuberculosis Aerosol Infection Studies. Applied Biosafety 16(3): 134-138, 2011

Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis. Plos Computational Biology 5(7): E1000423, 2009